Because CEA increased, to control the condition, the dose was adjusted to 400 mg; a review of CEA showed a decreasing trend, and assessment imaging suggested the disease was stable.
← all excerpts
Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
1
—
—